The drug was approved in 1998 for use in high-risk children, based on research showing benefits for certain children, including premature infants born at 35 weeks or earlier. The medicine is given in a series of injections, and is a costly treatment.
The AAP has recommended scaling back on the use of the medicine, saying that medical evidence shows that the drug benefits very few children other…
